Slide 1: Uscom (UCM) – Medical Devices and Revenue Growth
Proactive Investors September 2015 For personal use only Uscom (UCM) – Medical Devices and Revenue Growth Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO The Measure of Li
Slide 2: Disclaimer
Disclaimer For personal use only This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, fina
Slide 3: Uscom: Fundamentals to drive value
Uscom For personal use only Products generate profit High growth (+50% pa), innovative medical device company Outstanding science Key cardiovascular pulmonary markets and multiple products De-risked technology Poised for strategic growth with recent acquisitions Valuable IP with high margins (75+%)
Slide 4: For personal use only
For personal use only 4
Slide 5: Uscom vision
Uscom vision For personal use only Company of the Year, 2014 Johnson & Johnson Innovation Industry Excellence Awards “A milestone driven global medical device company with real products, real revenue, real growth and an aggressive growth strategy” 5
Slide 6: Current Business
Current Business For personal use only Premium noninvasive cardiovascular and pulmonary monitoring devices Addressing the growing threat of superbugs, heart failure, hypertension and asthma Validated, clinically accepted, cost and life saving devices with critical applications IP protected with regu
Slide 7: New Acquisition
New Acquisition For personal use only Uscom has acquired 100% of Thor Laboratories - Asthma * Company Overview Uscom benefits High fidelity digital Doppler spirometry devices Cash flow positive, revenue of $500k Established manufacturing - 15 years Accredited international manufacturing Global reach
Slide 8: New Products - Asthma
Aus competitor $75m New Products - Asthma For personal use only Products in Market New Products Digital Doppler Spirometer New – AsthmaHero Home use Drug delivery measure Telemetry to iPhone app Smart spacer Patient interactive With Diagnostics and WIFI Digital wifi spirometer New - BreatheSmart Dig
Slide 9: Strategic growth
Strategic growth For personal use only Complementary products and technology Fluid, Sepsis Hypertension & COPD & Heart Failure Vascular Health & Asthma US 1.3bn market * US 1.7bn market * US 400m market * CAGR of 7.6% * CAGR of 11.5% * CAGR of 6.5% * CE, FDA, TGA, CFDA CE, FDA, TGA CE, TGA, FDA USCO
Slide 10: De-Risked technology
De-Risked technology For personal use only Featured in 400+ peer reviewed publications and presentations Sepsis, Heart failure, Hypertension, Fluid management, Emergency, Pediatrics, Cardiac transplantation, Electrophysiology, Emergency transport, Anesthesia, Liver transplantation, ICU, Pre-eclampsi
Slide 11: Uscom People - Global
Uscom People - Global For personal use only Nick Schicht Steve Haken Andrew Kenig Denise Pater Tina Wu Rik Denicke Rob Phillips Global Euro Aus Global Global USA Global Bev Jacobson Richard Scott George Tang Lindy Belleza George Ferenczi Hagay Gilad Steve Wilson Global Global Aus Aus Global Aus USA
Slide 12: Current growth
Current growth For personal use only Revenue and Income Distribution Agreements $2,500,000 40 38 $2,039,426 $2,000,000 35 30 27 $1,500,000 $1,377,716 25 $1,010,942 20 $1,000,000 15 12 10 $500,000 5 $0 0 2013 2014 2015 2013 2014 2015 Distribution – sales – revenue 12 Thor acquisition adds distributio
Slide 13: Operations growth
Operations growth 1. Uscom Limited Maintaining growth 2. 3. Uscom UK Uscom Budapest For personal use only 4. Uscom Inc US • • •• 2 • •• • • •• • ••• 3 • • • • •• 4 •• •• • • • • • • • • Key Markets •• 1. AsiaPAC – 65% • • • 1 2/3. Europe – 27% 4. Nth America – 8% US Focus 2016 Stephen Wilson – Forme
Slide 14: Revenue Targets
Revenue Targets For personal use only Thor Total Revenue 20,000,000 18,000,000 16,000,000 BP+ 14,000,000 12,000,000 Thor $ 10,000,000 BP+ USCOM 8,000,000 USCOM 6,000,000 4,000,000 2,000,000 0 2015 2016* 2017* 2018* 2019* 2020* 14 $20m revenue by 2020 - 5 year CAGR of 58%
Slide 15: The Future
The Future For personal use only Value Cascade Products Sales Operations Opportunities USCOM 1A Current distribution Global operations Dividend Uscom BP+ Thor distribution Increased products Share price growth Spirotube New distribution Increased scale Transaction Otthon of Completion Major partners
Slide 16: Business Risks & Mitigants
Business Risks & Mitigants For personal use only Risks Mitigants Global markets unpredictable Diversified and expanded products Competitiveness of market sectors Senior sales and marketing personnel Thor integration & key staff retention Earn outs in Thor deal structure Ongoing Thor business managem
Slide 17: UCM Investment
UCM Investment For personal use only ASX 10yr CAGR 14 UCM sales growth 12 2014 – 67% 10 2015 – 59% 8 % 6 4 2 0 Mining Financials Health BHP NAB Resmed -2 Health outperforms! 17 *Dividend exclusive *25th August
Slide 18: Market anomaly - opportunity
Market anomaly - opportunity For personal use only Opposing forces! Disconnect between performance and price UCM share price UCM Revenue and Income $4,000,000 $3,500,000 $3,500,000 $3,000,000 $2,500,000 $2,039,426 $2,000,000 $1,500,000 $1,377,716 $1,010,942 $1,000,000 $500,000 $0 2013 2014 2015 2016
Slide 19: Uscom
Uscom For personal use only Value investment ✓ Strong growth phase ✓ Positioned for on going growth ✓ Strong underlying business ✓ Premium global markets ✓ ✓ Diversified and lifesaving technologies✓ Sector leading management ✓ Aggressive global growth strategy ✓ Right time ✓ 19
Slide 20: Thanks
Proactive Investors September 2015 For personal use only Uscom (UCM) – Medical Devices and Revenue Growth Thanks Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO